Presentation is loading. Please wait.

Presentation is loading. Please wait.

Thrombin activatable fibrinolysis inhibitor in Behçet's disease

Similar presentations


Presentation on theme: "Thrombin activatable fibrinolysis inhibitor in Behçet's disease"— Presentation transcript:

1 Thrombin activatable fibrinolysis inhibitor in Behçet's disease
Ayhan Donmez, Kenan Aksu, Handan Ak Celik, Gokhan Keser, Seckin Cagirgan, Serdar Bedii Omay, Vedat Inal, Hikmet Hakan Aydin, Murat Tombuloglu, Eker Doganavsargil  Thrombosis Research  Volume 115, Issue 4, Pages (January 2005) DOI: /j.thromres Copyright © 2004 Elsevier Ltd Terms and Conditions

2 Figure 1 TAFI plasma levels (mean±S.E.M.) for control, thrombosis (+), thrombosis (−) and total BD. All groups significant differences vs. control subjects (P<0.001). Thrombosis Research  , DOI: ( /j.thromres ) Copyright © 2004 Elsevier Ltd Terms and Conditions


Download ppt "Thrombin activatable fibrinolysis inhibitor in Behçet's disease"

Similar presentations


Ads by Google